Icotyde (Icotrokinra)

Icotrokinra is a medicine used to treat moderate to severe plaque psoriasis. It's taken as a pill by mouth. It works by blocking a signal in the immune system, called IL-23, that drives the skin inflammation in psoriasis.

Brand names:Icotyde
Medication

What people taking Icotyde (Icotrokinra) report

Every report comes from a Lived member, sent anonymously.

Have you tried Icotyde (Icotrokinra) for Psoriasis?

NameHow it went

About Icotyde (Icotrokinra)

What It's For

Icotrokinra, sold under the brand name Icotyde, is a once-daily prescription pill for moderate-to-severe plaque psoriasis. Plaque psoriasis is a long-term immune condition that causes itchy or sore patches of thick, red, scaly skin, often on the elbows, knees, scalp and back. Icotrokinra is approved in the US for adults and for children 12 and older who weigh at least 88 pounds (40 kg). It is meant for people whose psoriasis is widespread or troublesome enough that creams and ointments are not enough, and a whole-body (systemic) medicine or light therapy (phototherapy) is a reasonable next step. It blocks the same immune signal, interleukin-23 (IL-23), that some established injectable psoriasis medicines target, such as Tremfya (guselkumab), but as a tablet rather than an injection. The US Food and Drug Administration approved it in 2026, and its approval covers plaque psoriasis only, not psoriatic arthritis or other conditions.

How It Works

In psoriasis, an overactive immune response in the skin speeds up the normal cycle of skin renewal. Skin cells that usually take about a month to rise to the surface do so in days, piling up as raised, scaly plaques. A central driver of that inflammation is IL-23, a signaling protein that keeps a chain of inflammatory immune activity going. Icotrokinra is a peptide (a short chain of protein building blocks) designed to attach tightly to the receptor that IL-23 normally binds. With the receptor occupied, IL-23 cannot pass on its signal. In studies, people taking it had lower levels of interleukin-17 (IL-17) and other inflammatory messengers further down that chain, in both blood and skin. Researchers do not fully understand how these changes add up to clearer skin, but they explain why the effect builds over weeks rather than days.

Dosage & Administration

Icotrokinra comes as a 200 mg tablet taken once a day. When and how it is taken matters more than with many pills: take it on waking, on an empty stomach, with water, and wait at least 30 minutes before eating. Food reduces how much of the medicine the body absorbs; in testing, taking it with a high-fat meal lowered absorption by more than 40%. Swallow the tablet whole and do not crush, split or chew it. People who have trouble swallowing pills can instead drop the tablet into at least 4 ounces (120 mL) of water, wait a few minutes for it to break up, swirl and drink it, then add another 4 ounces of water to the cup and drink that too, all within 15 minutes. The mixture may look cloudy or yellow with small pieces, which is expected and safe to swallow. If a dose is missed, take it as soon as possible, then go back to the usual schedule the next day. Before the first dose, the prescriber may check for tuberculosis and will want recommended vaccines brought up to date.

Side Effects

In the trials, side effects were generally uncommon. Headache was the most frequent, affecting about 4% of people taking icotrokinra compared with about 3% taking a placebo (a dummy pill). Nausea, cough, tiredness and fungal infections such as athlete's foot or thrush each affected about 1%. Because icotrokinra dampens part of the immune response, it can make infections more likely. Serious infections were rare in the first 16 weeks of the trials (0.2% of people, versus 0.4% on placebo), but the risk still deserves attention. Contact the prescriber right away for signs of infection, such as fever, sweats or chills, a cough or shortness of breath, warm, red or painful skin or sores that look different from your psoriasis, burning or frequent urination, or diarrhea or stomach pain. The prescriber may pause icotrokinra until a significant infection clears.

Interactions & Warnings

Tuberculosis (TB) is the main concern to address before starting. The prescriber may test for TB, may treat an old or inactive TB infection first, and will watch for TB symptoms such as unexplained fever, a persistent cough or trouble breathing during and after treatment. Icotrokinra is avoided in people with active TB and is generally not started during a significant active infection. People who have infections that keep coming back should weigh the risks with their prescriber. Avoid live vaccines while taking icotrokinra, and tell whoever gives a vaccine that you take it. Ideally, recommended vaccines are completed before treatment begins, since it is not yet known how well vaccines work during treatment. No interactions with other medicines have been identified, and lab studies suggest it does not interfere with the enzymes that clear many common drugs. Formal interaction studies have not been done, though, so the prescriber and pharmacist should still know about every medicine and supplement you take. In people with moderate or severe kidney disease, the drug reaches about two and a half times the usual level, so they are watched more closely for side effects. There is not enough information to know whether icotrokinra is safe in pregnancy. In animal studies, harm to rabbit pregnancies appeared only at exposures far above the human dose. A pregnancy safety study is collecting outcomes for people who take it while pregnant. It is also not known whether it passes into breast milk, so anyone pregnant, planning pregnancy or breastfeeding should talk through the options with the prescriber.

What to Expect

Icotrokinra works gradually. In the trials, some people noticed meaningfully less itching within four weeks, and the main results were measured at 16 weeks. By then, about two-thirds of adults had clear or almost clear skin, compared with about 1 in 10 on placebo. About half or more had at least a 90% improvement on the Psoriasis Area and Severity Index (PASI), a standard score of how much skin is affected and how severe it is, and roughly a quarter to a third had completely clear skin. In two trials, icotrokinra did better on these measures than Sotyktu (deucravacitinib), another once-daily psoriasis pill. Some people kept improving through 24 weeks. Results vary, and not everyone reaches clear skin. Icotrokinra controls psoriasis rather than curing it. When people who had responded well were switched to placebo, most lost much of their improvement, typically within about 10 weeks, while about 8 in 10 who continued kept their response through a full year. For that reason it is usually taken long term, and stopping is best planned with the prescriber. Because the medicine is new, experience beyond about a year of use is still limited. Follow-up visits check how well the skin is clearing, watch for infections, and decide whether to continue or change treatment.

Questions to Ask Your Doctor

  1. 1.Why might icotrokinra suit me better than an injectable biologic or another pill such as Sotyktu?
  2. 2.Is a strict empty-stomach routine each morning realistic for me, and what should I do on days it goes wrong?
  3. 3.Do I need a TB test or any vaccines before I start, and which vaccines should I avoid while taking it?
  4. 4.When will we judge whether it is working, and what would we try if it is not enough?
  5. 5.What is the plan if I want to stop treatment or become pregnant?

Last reviewed • Oct 2026

Educational content, not medical advice.